[go: up one dir, main page]

AR118898A1 - Dominios variantes para multimerizar proteínas y su separación - Google Patents

Dominios variantes para multimerizar proteínas y su separación

Info

Publication number
AR118898A1
AR118898A1 ARP200101330A ARP200101330A AR118898A1 AR 118898 A1 AR118898 A1 AR 118898A1 AR P200101330 A ARP200101330 A AR P200101330A AR P200101330 A ARP200101330 A AR P200101330A AR 118898 A1 AR118898 A1 AR 118898A1
Authority
AR
Argentina
Prior art keywords
proteins
immunoglobulin
separation
variant domains
multimerizing
Prior art date
Application number
ARP200101330A
Other languages
English (en)
Inventor
Kruif Cornelis Adriaan De
Peter Brian Silverman
Richard Bonneau
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of AR118898A1 publication Critical patent/AR118898A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se refiere a medios y métodos para producir y aislar proteínas inmunoglobulinas que comprenden un primer y un segundo polipéptido de inmunoglobulina, en particular medios y métodos para producir y separar proteínas que comprenden un primer y un segundo polipéptido de inmunoglobulina. Mediante la inclusión de variaciones en los aminoácidos, y dominios de separación variantes de una célula que produce la proteína inmunoglobulina deseada, se puede separar de las mezclas de proteínas inmunoglobulinas una proteína inmunoglobulina deseada tal como se produjo.
ARP200101330A 2019-05-09 2020-05-08 Dominios variantes para multimerizar proteínas y su separación AR118898A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19173633 2019-05-09

Publications (1)

Publication Number Publication Date
AR118898A1 true AR118898A1 (es) 2021-11-10

Family

ID=66476558

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101330A AR118898A1 (es) 2019-05-09 2020-05-08 Dominios variantes para multimerizar proteínas y su separación

Country Status (17)

Country Link
US (1) US20210054049A1 (es)
EP (1) EP3966238A2 (es)
JP (2) JP7760377B2 (es)
KR (1) KR20220017909A (es)
CN (2) CN114702587A (es)
AR (1) AR118898A1 (es)
AU (2) AU2020268684B2 (es)
BR (1) BR112021022405A2 (es)
CA (1) CA3139402A1 (es)
IL (1) IL287928A (es)
MA (1) MA55884A (es)
MX (1) MX2021013646A (es)
NZ (1) NZ782091A (es)
PH (1) PH12021552833A1 (es)
SG (1) SG11202112399PA (es)
TW (1) TW202108613A (es)
WO (1) WO2020226502A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020019795A2 (pt) * 2018-03-30 2021-01-05 Merus N.V. Anticorpo multivalente
CA3202339A1 (en) * 2020-12-18 2022-06-23 Mei Jang Protein compositions and methods for producing and using the same
CN120641444A (zh) 2022-12-27 2025-09-12 美勒斯公司 产生双重特异性蛋白的方法
WO2025221138A1 (en) 2024-04-15 2025-10-23 Merus N.V. Cd3 binding domains
WO2025230410A1 (en) 2024-04-30 2025-11-06 Merus N.V. Multispecific antibody-drug conjugates
WO2025230409A1 (en) 2024-04-30 2025-11-06 Merus N.V. Multispecific antibody-drug conjugates

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
US7135287B1 (en) * 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
CA2484930A1 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
CN105884893A (zh) 2002-07-18 2016-08-24 莫鲁斯有限公司 抗体混合物的重组生产
UA87979C2 (ru) * 2002-08-19 2009-09-10 Астразенека Аб Человеческое моноклональное антитело, которое нейтрализует моноцитарный хемоатрактантный белок (мср-1)
EP2053062A1 (en) * 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
EP1858925A2 (en) * 2005-01-12 2007-11-28 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
JP5144499B2 (ja) * 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
CN101874042B9 (zh) * 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
PL3456190T3 (pl) 2008-06-27 2022-06-06 Merus N.V. Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
US9683052B2 (en) * 2011-03-25 2017-06-20 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
TW201817745A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
DK2766392T3 (da) 2011-10-10 2019-10-07 Xencor Inc Fremgangsmåde til oprensning af antistoffer
EP2787078B1 (en) 2011-10-31 2019-05-22 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
PT2838917T (pt) * 2012-04-20 2019-09-12 Merus Nv Métodos e meios para a produção de moléculas similares a ig heterodiméricas
CN104045714B (zh) * 2013-03-14 2019-01-11 南京金斯瑞生物科技有限公司 曲妥珠单抗突变体IgG及其应用
WO2014145806A2 (en) 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins
ES2816624T3 (es) 2014-02-28 2021-04-05 Merus Nv Anticuerpos que se unen a EGFR y ERBB3
WO2016016299A1 (en) * 2014-07-29 2016-02-04 F. Hoffmann-La Roche Ag Multispecific antibodies
MA41375A (fr) * 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
WO2017213267A1 (en) * 2016-06-10 2017-12-14 Eisai R&D Management Co., Ltd. Lysine conjugated immunoglobulins
EP3472197A1 (en) * 2016-06-15 2019-04-24 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
TWI887193B (zh) 2017-07-06 2025-06-21 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
EA202090003A1 (ru) 2017-07-06 2020-06-18 Мерус Н.В. Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка
BR112020000228A2 (pt) 2017-07-06 2020-07-14 Merus N.V. anticorpos que modulam uma atividade biológica expressa por célula
PL3665198T3 (pl) 2017-08-09 2025-06-09 Merus N.V. Przeciwciała wiążące egfr i cmet
WO2019148410A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
WO2019148412A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
BR112020019795A2 (pt) 2018-03-30 2021-01-05 Merus N.V. Anticorpo multivalente
CN110272495A (zh) * 2019-06-11 2019-09-24 南京华岩生物技术有限公司 一种能结合两种抗原的双特异性结合的免疫球蛋白及其用途

Also Published As

Publication number Publication date
MX2021013646A (es) 2022-01-31
CN114430745A (zh) 2022-05-03
EP3966238A2 (en) 2022-03-16
AU2020268684A1 (en) 2021-12-09
CN114702587A (zh) 2022-07-05
PH12021552833A1 (en) 2023-01-16
CA3139402A1 (en) 2020-11-12
TW202108613A (zh) 2021-03-01
WO2020226502A2 (en) 2020-11-12
IL287928A (en) 2022-01-01
WO2020226502A3 (en) 2021-02-04
AU2020268684B2 (en) 2025-07-03
AU2025208511A1 (en) 2025-08-14
KR20220017909A (ko) 2022-02-14
JP2022534674A (ja) 2022-08-03
BR112021022405A2 (pt) 2022-04-19
WO2020226502A9 (en) 2022-03-03
JP2025120179A (ja) 2025-08-15
NZ782091A (en) 2025-08-29
US20210054049A1 (en) 2021-02-25
JP7760377B2 (ja) 2025-10-27
MA55884A (fr) 2022-03-16
SG11202112399PA (en) 2021-12-30

Similar Documents

Publication Publication Date Title
AR118898A1 (es) Dominios variantes para multimerizar proteínas y su separación
MX2025003310A (es) Integracion dirigida de acidos nucleicos
AR120511A2 (es) Producción de proteínas heteromultiméricas
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
MX2018009989A (es) Composiciones funcionales derivadas de frijol mungo.
MX389073B (es) Método para producir una proteína de fusión de anticuerpo.
ECSP077282A (es) Proceso para la concentración de anticuerpos y productos terapéuticos de los mismos
HRP20191446T1 (hr) Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
BR112012025326A2 (pt) "extração seletiva de proteínas de algas de água salgada"
MX372711B (es) Metodos para la purificacion de arilsulfatasa a.
CR20240116A (es) RECEPTORES QUIMÉRICOS DE FLT3 Y MÉTODOS DE USO DE LOS MISMOS (Divisional 2018-518)
RU2013140685A (ru) ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ
AR115695A1 (es) Moléculas proteicas multifuncionales que comprenden decorina y uso de estas
AR094375A1 (es) Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular
EA201070987A1 (ru) Очищенные гибридные белки иммуноглобулина и способы их очищения
MX2016004564A (es) Cultivo celular metabolicamente optimizado.
WO2014146074A3 (en) Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
MX2018009331A (es) Metodos para extraer proteinas a partir de un material a base de sangre.
MX2021000934A (es) Linfocitos t que contienen nef y métodos para producirlos.
MX2019007316A (es) Eliminacion de acidos nucleicos y fragmentos de los mismos de un material de biomasa.
BR112016012229A2 (pt) métodos de produção de polipeptídeos
CO2023003453A2 (es) Proteínas de fusión inmunogénicas de coronavirus y métodos relacionados
HRP20231139T1 (hr) Proizvodnja heteromultimernih proteina upotrebom stanica sisavaca
WO2018120843A9 (zh) 一种三功能分子及其应用
AR100131A1 (es) Proceso de purificación de gonadotropina